esmo-acf cml: guide for patients - japanesecml: a guide for patients - information based on esmo...
TRANSCRIPT
![Page 1: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/1.jpg)
![Page 2: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/2.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 1
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ ¢æ§éªšé«æ§çœè¡ç ïŒæ£è ããã®æåŒã
ESMO 蚺çã¬ã€ãã©ã€ã³ã«åºã¥ããæ£è ããåãæ å ±
æ¥æ¬èªèš³ççºè¡ã«ããã
ããæ£è ããã®æãåå®ãªèŠæã®äžã€ãããèªèº«ã®çœ¹æ£ããããã«é¢ããæ£ç¢ºãªæ²»çæ å ±ãåŸ
ãããšã§ããæ¥æ¬çæ²»çåŠäŒã§ã¯åçš®åŠè¡å£äœãçºåããããé¢é£èšºçã¬ã€ãã©ã€ã³ã®å ¬éãã
ãæ²»çå šè¬ã«é¢ãã暪æçããæ²»çæ¯æçæ³ã«é¢ãã蚺çã¬ã€ãã©ã€ã³ã®çå®ãªã©ãè¡ã£ãŠåã
ãŸãããäžéšã®ããã§ã¯æ£è ããããã®ã家æã«ãããããããäžè¬åããã®èšºçã¬ã€ãã©ã€ã³
ãçºåãããŠããŸãããããããç¶²çŸ ããé åã¯ãŸã ååãšã¯èšããªãç¶æ³ã§ãã
ããæ£è ããã«ãšã£ãŠæã倧åãªæšæºæ²»çã«ã€ããŠåããæã解説ããã¬ã€ãã©ã€ã³ãæäŸã
ãç®çã§ãæ¬åŠäŒåçäºé·ã®è¥¿å±±æ£åœŠå çãšåœæã®æ¬§å·èšåºè «çåŠäŒïŒEUROPEAN SOCIETY OF
MEDICAL ONCOLOGY, ESMOïŒäŒé· ROLF A. STAHEL å çãåæãããESMO/ANTICANCER
FUND GUIDES FOR PATIENTS æ¥æ¬èªèš³ããçºåããããšãšãªããŸãããæ¥æ¬ãšæ¬§å·ã§ã¯äœ¿çšå¯
èœãªæè «çè¬ãæè¡æ¹æ³ãªã©ãè¥å¹²ç°ãªããŸãããç æ ã®ç解ãæ²»çã®æµããªã©æ£è ããã«ãã
ãããã解説ããã蚺çã¬ã€ãã©ã€ã³ã¯å€§å€è²Žéãªæ å ±æºãšãªãããšãæåŸ ãããŸãããŸããæ¬
éŠã«ãããŠããããæ£è ããåãã®èšºçã¬ã€ãã©ã€ã³ãçºåããåŸæŒããšããªããæ£è ããåã
ã¬ã€ãã©ã€ã³ã®ããæ¹ã«ã€ããŠã倧å€åèã«ãªããã®ãšæåŸ ããŠãããŸããæ¬ã·ãªãŒãºã®ç¿»èš³ã
äœæã«å€å€§ãªããå°œåãé ããæ¥æ¬çæ²»çåŠäŒçäºãæè²å§å¡äŒãç·šéå§å¡äŒã®çæ§ãã¯ããã
ãæ¯æŽãäžãã£ããã¹ãŠã®çæ§ã«å¿ããæè¬ç³ãäžããŸãã
å¹³æ 28 幎 7 æ æ¥æ¬çæ²»çåŠäŒ
çäºé· åå·éå
ãã®åºŠãESMO ïŒæ¬§å·èšåºè «çåŠäŒïŒã®çºè¡ããâESMO GUIDES FOR PATIENTSâã
ãESMO æ£è ããã®æåŒãããšããŠæ¥æ¬èªèš³ããæ¥æ¬ã®çæ£è ããã«æäŸããããšã«ãªããŸã
ãã
æè¿ã®çæ²»çã®çºå±ã¯ãããŸãããçæ£è ããã«ãšã£ãŠã¯æ°å€ãã®æ²»çæ³ã®éžæãå¯èœã«ãªã£
ãŠããŠããŸããæ£è ããã«ãšã£ãŠã¯æå ±ã§ãããããããã£ãœãã§ã¯å€§éã«çºä¿¡ãããæ å ±ã®äž
ã§ãçã«æºããå»çåŸäºè ãšæ£è ãããšã®éã§ã®ç¥èã®ã®ã£ãããåé¡ã«ãªã£ãŠããŸããããµã
ãããæ å ±ã®äžã§ãçã«å¯Ÿããæ£ç¢ºãªæ å ±ãæŽçããèªåã«æé©ãªæ²»çæ³ãèŠã€ãåºãããšã¯æ¬
åœã«é£ããããšã§ããããšæããŸãããã®ãããªæ å ±ã®æµ·ã®äžã§è¿·ã£ãŠããçæ£è ããã«å¯Ÿãã
ã¬ã€ã圹ãšããŠããã®ãESMO æ£è ããã®æåŒããã¯äœæãããŠããŸãã
ãã®æåŒãã¯âESMO/ANTICANCER FUND GUIDES FOR PATIENTSâ ããåºæ¥ãã ãå¿ å®ã«
æ¥æ¬èªèš³ããããšã«ããŠãããŸãããšãŒããããšæ¥æ¬ã§ã¯ãä¿éºå¶åºŠãå«ãå»çäºæ ãè¥å¹²ç°ãª
ã£ãŠããŸãã®ã§ããã®æåŒãããã®ãŸãŸæ¥æ¬ã®æ£è ããã«åœãŠã¯ãŸããªãããšãããããšæããŸ
ããããå€æã«å°ãããšããããŸãããã䞻治å»ã®å çã«çŽæ¥ãèãããã ããã°ãšæããŸãã
ãã®æåŒããæ¥æ¬ã®çæ£è ããã«ãšã£ãŠæçšãªæ¡å 圹ãšãªãããšãæåŸ ããŠããŸãã
æåŸã«ããã®æåŒãã®äœæã«å°œåããã ããæ¥æ¬çæ²»çåŠäŒæè²å§å¡äŒããããŠç·šéå§å¡äŒã®å
çæ¹ã«å¿ããæè¬ããããšæããŸãã
å¹³æ 28 幎 7 æ æ¥æ¬çæ²»çåŠäŒ
ç·šéå§å¡äŒå§å¡é· å°å·ä¿®
![Page 3: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/3.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 2
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ ¢æ§éªšé«æ§çœè¡ç ïŒæ£è ããã®æåŒã
ESMO 蚺çã¬ã€ãã©ã€ã³ã«åºã¥ããæ£è ããåãæ å ±
翻蚳 æ±äº¬æ æµäŒå»ç§å€§åŠ è «çã»è¡æ¶²å ç§ïŒ
çºå³¶æºäººãåéšæŠå²ãç¥å±±ç¥å€ªéã倧島ããããæéšå€§æš¹ãæå±±åçŽãçžçŸœæ ä»
ãã®æ£è ããçšæåŒãã¯ãæ£è ãããšã家æããæ ¢æ§éªšé«æ§çœè¡ç ïŒCMLïŒãã©ã®ãã
ãªç æ°ã§ããããããç解ããæ ¢æ§éªšé«æ§çœè¡ç ã®ç¶æ ã«å¿ããæåã®æ²»çãåããããšã
ã§ããããã«ãããå æåºé(Anticancer Fund)ã«ããæºåããããã®ã§ããæ£è ããã«
ã¯ããèªèº«ã®æ ¢æ§éªšé«æ§çœè¡ç ã®ç ç¶ãç æã«ãã£ãŠãã©ã®ãããªæ€æ»ãæ²»çãå¿ èŠã§ãã
ããæ åœå»ã«èããŠããã ãããšããå§ãããŸããããã«æ²èŒãããŠããå»åŠçãªæ å ±ã¯æ¬§
å·èšåºè «çåŠäŒ(European Society for Medical Oncology: ESMO)ã®æ ¢æ§éªšé«æ§çœè¡ç
ã®ããã®èšºçã¬ã€ãã©ã€ã³ã«åºã¥ãããã®ã§ãããã®æ£è ããçšæåŒã㯠ESMO ã®ååã®
ããšã§äœæãããESMO ã®èš±å¯ã®ããšé åžãããŠããŸãããã®æåŒãã¯å»åž«ã«ããå·çã
ããå°éå»åã蚺çã¬ã€ãã©ã€ã³ã®äž»èŠãªèè ãå«ããESMO æå±ã®äºåã®è «çå»ã«ãã£
ãŠç£ä¿®ãåããŠããŸãããŸããESMO ã®ããæ£è ã¯ãŒãã³ã°ã°ã«ãŒãã®ä»£è¡šè ã«ãç£ä¿®ã
åããŠããŸãã
ããå æåºéïŒAnticancer FundïŒã«é¢ããæ å ±ãæŽã«ç¥ãããå Žåã¯ä»¥äžã®ãµã€ããžã¢
ã¯ã»ã¹ããŠäžããïŒ www.anticancerfund.org
欧å·èšåºè «çåŠäŒïŒESMOïŒã«ã€ããŠæŽã«ç¥ãããå Žåã¯ä»¥äžã®ãµã€ããžã¢ã¯ã»ã¹ããŠäžã
ãïŒ www.esmo.org
ïŒãä»ããçšèªã«é¢ããŠã¯ãå·»æ«ã«æ³šéããããŸãã
ãæ¥æ¬èªçã翻蚳ããæ¥æ¬çæ²»çåŠäŒãã泚èšã
ãã®æåŒãã¯æ¬§å·èšåºè «çåŠäŒïŒESMOïŒã«ãã 2013 幎ã«äœæããããã®ããESMO ãš
ã®å¥çŽã«åºã¥ããæ¥æ¬çæ²»çåŠäŒãåæã«å¿ å®ã«æ¥æ¬èªã«ç¿»èš³ãããã®ã§ãã
![Page 4: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/4.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 3
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
ç®æ¬¡
æ ¢æ§éªšé«æ§çœè¡ç ã®å®çŸ©ïŒCMLïŒ ........................................................................................................................ 4
æ ¢æ§éªšé«æ§çœè¡ç ã®é »åºŠã¯ïŒ .................................................................................................................................... 5
æ ¢æ§éªšé«æ§çœè¡ç ã®åå ã¯ïŒ .................................................................................................................................... 6
æ ¢æ§éªšé«æ§çœè¡ç ã®èšºæã¯ïŒ .................................................................................................................................... 7
é©åãªæ²»çãåããã«ã¯äœãéèŠãïŒ ................................................................................................................ 8
æ²»çã®éžæè¢ãšããŠäœãããã®ïŒ ...................................................................................................................... 10
æ²»çãéå§ããã次ã¯ã©ãããã? ................................................................................................................... 14
çšèªã®èª¬æ ...................................................................................................................................................................... 17
ãã®ããã¹ã㯠Dr Holbrook E.K. Kohrt (Anticancer Fund) ã«ããå·çããã Dr Gauthier Bouche (Anticancer Fund)ãDr Svetlana Jezdic (ESMO)ãDr Michele Baccarani (ESMO)ãPr Martin Dreyling (ESMO) ãMr Jan Geissler (ESMO ããæ£è ã¯ãŒãã³ã°ã°ã«ãŒã)ã«ããç£ä¿®ãããŸããã
ä»åã®æ¹èšç(2013)ã®æ¹èšç®æã¯ãESMO 蚺çã¬ã€ãã©ã€ã³ã®ææ°çãåæ ããŠããŸããæ¹èšã¯ Dr Gauthier Bouche (Anticancer Fund) ã«ãã£ãŠãªããã Dr Svetlana Jezdic (ESMO)ãDr Michele Baccarani (ESMO)ã Pr Martin Dreyling (ESMO)ã«ããç£ä¿®ãããŸããã
![Page 5: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/5.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ ¢æ§éªšé«æ§çœè¡ç ã®å®çŸ© ïŒCMLïŒ
çœè¡ç ã¯è¡æ¶²ã®ããã®äžçš®ã§ããçœè¡ç ã¯ããåããè¡æ¶²çŽ°èã«ãã£ãŠãããã€ãã®çš®é¡ã«
åãããŸããæ ¢æ§éªšé«æ§çœè¡ç ã®ãæ ¢æ§ãã¯ç æ°ããã£ããé²è¡ããããšããã骚é«æ§ãã¯
æ£åžžãªç¶æ ã§ã¯æçããèµ€è¡ç*ã»çœè¡ç*ã»è¡å°æ¿*ã«ãªããã幌è¥ãªé è¡å¹¹çŽ°èã®ããšã
æå³ãããã®çŽ°èãããã«ãªã£ãããã§ããæ ¢æ§éªšé«æ§çœè¡ç ã®éªšé«æ¶²äžã§ã¯ã幌è¥é¡ç²ç
*ãåŸéªšé«ç*ã骚é«ç*ãšãã£ãæ§ã ãªæç段éã®éªšé«çŽ°èãéå°ã«ç£çãããŸãããŸãè¡
å°æ¿ã奜塩åºç(骚é«çŽ°èã®äžçš®ã§ã)ãé«é »åºŠã§éå°ã«ç£çãããŸãã骚é«æ¶²äžã§ã骚é«çŽ°
èãéå°ã«äœããç¶ãããšãæçµçã«ã¯æ£åžžãªèµ€è¡çã®ç£çãæå¶ãããŸããèµ€è¡çã¯äœå
ã®çŽ°èã«é žçŽ ãäŸçµŠãããšããéèŠãªåœ¹å²ãæ ããŸãããŸãæ¢è¡ã®ããã«å¿ èŠãªè¡å°æ¿ã®ç£
çãåæ§ã«æå¶ãããè¡å°æ¿æžå°ãèªããããããšããããŸãã
æ ¢æ§éªšé«æ§çœè¡ç ã¯å¥åº·èšºæã§å¶ç¶ã«èšºæãããå Žåãã貧è¡*ã®é²è¡ã«äŒŽãåŠæ æãè¡å°
æ¿ã®æžå°ã«äŒŽãåºè¡çç¶ãè ¹çãŸãã¯è ¹éš*ã®äžå¿«æãªã©ã®çç¶ã«ãã蚺æãããå Žåãã
ããŸããèŸèãè «å€§ãããèŸè «ããé²è¡ãããšå·Šèžéšããè ¹éšã®äžå¿«æããããã¯äŸ¿éã®ç°
åžžãªã©ãèµ·ãããŸãããã®ä»ã®çç¶ãšããŠãçºç±ãæ¯åãã骚çãªã©ããããŸãã蚺ææã¯ã
ã»ãšãã©ã®æ£è ããã§æ«æ¢¢è¡æ¶²äžã®çœè¡çæ°ãåºæºå€ãè¶ ããŠå¢å ããŠããŸãã
![Page 6: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/6.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 5
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ ¢æ§éªšé«æ§çœè¡ç ã®é »åºŠã¯ïŒ
ç·æ§ã®åç«è ºçã女æ§ã®ä¹³çã®çºççã«æ¯ã¹ãæ ¢æ§éªšé«æ§çœè¡ç ã®çºççã¯é«ããããŸããã
欧å·ã§ã¯ãæ¯å¹Ž 10 äžäººåœãã 1ïœ2 人ã®æ£è ãããæ ¢æ§éªšé«æ§çœè¡ç ãšèšºæãããŸããå°
å ã«æ ¢æ§éªšé«æ§çœè¡ç ãçºçããããšã¯éåžžã«çšã§ããæ ¢æ§éªšé«æ§çœè¡ç ã¯å¹Žéœ¢ãšãšãã«å¢
å ããæ£è ããã®å¹Žéœ¢ã®äžå€®å€ã¯ã ããã 60 æ³ååŸã§ããæ ¢æ§éªšé«æ§çœè¡ç ã®æ£è ããã®
ååžã«å°åå·®ã¯èŠãããŸããã
![Page 7: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/7.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 6
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ ¢æ§éªšé«æ§çœè¡ç ã®åå ã¯ïŒ
æ ¢æ§éªšé«æ§çœè¡ç ã®åå ã¯ãé è¡å¹¹çŽ°è*ã«èµ·ããç¹å®ã®éºäŒåã®ç°åžž*ã«èµ·å ããããšãç¥
ãããŠããŸããããããªããããªããã®ãããªéºäŒåã®ç°åžžãèµ·ããã®ãã¯äžæã§ãã
ãã®ç¹æ®ãªéºäŒåç°åžžã¯ãéºäŒå*ãæ£åžžãªç¶æ ããéžè±ããŠåæ§æããããšã«ãã£ãŠåŒã
èµ·ããããŸãã人ã«ã¯ 46 æ¬ã®æè²äœããããŸããããã®ãã¡ 9 çªæè²äœ (ABL*
ïŒAbelson murine leukemiaïŒéºäŒåãååš )ãš 22 çªæè²äœ (BCR*ïŒBreakpoint
cluster regionïŒéºäŒåã
ååš)ãéäžããåããå ¥ã
æ¿ãã£ãŠã§ããæè²äœïŒçž
äºè»¢åº§ïŒããã£ã©ãã«ãã£
ã¢æè²äœãšãã³ãæ ¢æ§éªšé«
æ§çœè¡ç ã«ç¹åŸŽçãªç°åžžã§
ãããã®ãã£ã©ãã«ãã£ã¢
æè²äœã¯ãæ ¢æ§éªšé«æ§çœè¡
ç ã® 95%ã®æ£è ããã®æ«
梢è¡ã骚é«æ¶²ã®çŽ°èã«èªã
ãããŸãã
ãã£ã©ãã«ãã£ã¢æè²äœã¯
ããã·ã³ãããŒãŒ*(现èå
ã®é µçŽ )ã§ãã BCR-ABL
éºäŒåãçºçŸãã现èã«æª
圱é¿ãåãŒããŸããããã·ã³ãããŒãŒã¯çŽ°èãäžæ»åãã现èã®å¢æ®*ãæ©ãã现èã®åå
ãé害ããŸãã
æ ¢æ§éªšé«æ§çœè¡ç çºçã®å±éºå å*ã¯å³å¯ã«ã¯ããã£ãŠããŸããã以äžã«çºçã®ãªã¹ã¯ãå
æããŸããããã®ãããªãªã¹ã¯ããªããŠãçœè¡ç ã¯çºçããŸãã
é«ç·éæŸå°ç·*ãžã®æŽé²ã¯ãæ ¢æ§éªšé«æ§çœè¡ç çºçã®ãªã¹ã¯ãå¢å ãããå¯èœæ§ãã
ããŸããååç匟ã®è¢«ççåè ãååçäºæ ã®çåè ããã㊠1950 幎以å(ä¿è·ã·
ãŒã«ããå°å ¥ãããå)ã®æŸå°ç·æåž«ã¯æ ¢æ§éªšé«æ§çœè¡ç ã®çºçãªã¹ã¯ãé«ãããšã
ç¥ãããŠããŸãã
å 霢ã¯æ ¢æ§éªšé«æ§çœè¡ç ã®çºçãªã¹ã¯ãå¢å ãããŸããã決ããŠãã®ãªã¹ã¯ã¯é«ã
ãã®ã§ã¯ãããŸãããç·æ§ã¯å¥³æ§ããããããã«å€ãçºç ããŸãã
蟲è¬*ããã³ãŒã³*ãžã®æŽé²ã¯æ ¢æ§éªšé«æ§çœè¡ç ã®çºççã軜床äžæããããšèšãããŠããŸãã
![Page 8: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/8.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 7
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ ¢æ§éªšé«æ§çœè¡ç ã®èšºæã¯ïŒ
æ ¢æ§éªšé«æ§çœè¡ç ã¯ãçœè¡ç ã«ããèªèŠçç¶ãŸãã¯æ€æ»å€ã®ç°åžžããçã£ãŠãããŸããèªèŠ
çç¶ãããå Žåããªãå ŽåïŒç¡çç¶*ïŒããããŸãããæ£è ããã®çç¶ãŸãã¯èšåºæèŠãšã
ãŠã¯ä»¥äžã®ãã®ããããããŸãã:
1. èŸè «ã å·Šäžè ¹éš*ã«ååšããèŸèãè «å€§ããŸããèŸè «ã«ããè ¹éšäžå¿«æãå·Šè©ã«æŸæ£
ããçã¿ãæºè ¹æã«ããé£æ¬²äœäžãè žã®å§æã«ããæ䟿ã®ç°åžžãããããŸããææã
äœéã®å¢å ãå·Šèžéšããè ¹éšã«ãããŠã®è «ç€ãèªããŸãã
2. åŠæ æã 貧è¡*ïŒèµ€è¡çæ°ãæžå°ããããšã«ããçããæ€æ»å€ãšããŠã¯ãããã¯ãªã
ã*å€ããã¢ã°ããã³*å€ãäœäžããŸãïŒãåå ã§å šèº«åŠæ æãåºçŸããŸãããããã
貧è¡ãé²è¡ãããŸã§çç¶ãèªèŠããªãå ŽåããããŸãã
3. åºè¡çç¶ãç åæã¯è¡å°æ¿æ°*ãå¢å ããããšããããŸããããããç ç¶ãé²è¡ãã
ãšçœè¡ç 现èã«ããæ£åžžéªšé«çŽ°èã眮ãæãããè¡å°æ¿ã®ç£çãäœäžããŸããçç¶
ãšããŠã¯ããããåºæ¥ããããªãã錻åºè¡ãå£è ç²èã®åºè¡ãç®äžã«ç¹ç¶åºè¡*ã玫
æãåºçŸããŸãã
äžèšã®æ§ãªçç¶ãããå Žåãè¡æ¶²æ€æ»ãè¡ããŸãã骚é«ã§äœãããè¡æ¶²çŽ°èã«ã¯ 1ïŒçœè¡ç
* 2ïŒèµ€è¡ç*3ïŒè¡å°æ¿*ããããŸããäžè¬çã«è¡ãããè¡æ¶²æ€æ»ã®ç°åžžã§ãçœè¡ç ã蚺æ
ãã糞å£ã«ãªãå ŽåããããŸããçœè¡çæ°(è¡æ¶²äžã®çœè¡ç 现è)ã®å¢å ãšãšãã«çœè¡çåç»
ã§ãçœè¡çã®æç段éã®æ¯çã®ç°åžž(å¢æ®ã®ç°åžž)ãèªãã奜塩åºç*ã®å¢å ãªã©ãã¿ãããŸ
ãã
æ ¢æ§éªšé«æ§çœè¡ç ã¯èšåºçç¶ãçœè¡ç*æ°ã®å¢å ã«ãã£ãŠçãã骚é«æ€æ»ïŒéªšé«çæ€*ïŒã«ã
ã£ãŠèšºæããªãããŸããå€ãã®æ£è ããã¯æ«æ¢¢è¡ã®æ€æ»ã§ãåèšã® 9 çªæè²äœãš 22 çªæ
è²äœã転座ããããšã§çãããã£ã©ãã«ãã£ã¢æè²äœ*ã蚌æããããšãã§ããŸãããã£ã©
ãã«ãã£ã¢æè²äœã¯åŸæ¥ã®çŽ°èéºäŒåŠçãªæ¹æ³ïŒéªšé«æ¶²ã®åè£æã®çŽ°èã现èéºäŒåŠ*ã«è§£
æããæ€æ»ïŒã§åå®ããããšãå¯èœã§ãããPCR*ïŒããªã¡ã©ãŒãŒé£éåå¿ïŒæ³ãšããç®ç
ãšãã DNA ãéžæçã«å¢å¹ ããææ³ãçšããååçç©åŠçãªæ¹æ³ããFISH *æ³ïŒèå in-
situ ãã€ããªãã€ãŒãŒã·ã§ã³æ³ïŒãšãããç®çãšããéºäŒåã«èå è²çŽ ã«ããå°ãã€ããè²
ã®å€åãããšã«æè²äœäžã«ããç°åžžãªéºäŒåé åãèŠã€ãåºã现èéºäŒåŠçæ€æ»*ã§ãåå®
ããããšãå¯èœã§ãããã®ãããªæ€æ»ã§ãã£ã©ãã«ãã£ã¢æè²äœãæ€åºãããå Žåã骚é«æ€
æ»ãè¡ããªãã§æ²»çãéå§ããå ŽåããããŸãã
骚é«æ€æ»ã¯å€å°çã¿ã䌎ãæ€æ»ã§ããèŠããæé㯠15 åçšåºŠã§ããå±æ麻é *ãçšããŸã
ã®ã§ãç©¿åºæã®çã¿ã¯ç·©åãããé垞匷ãçã¿ã¯æããŸããã
çµç¹èšºæã®æè²ãåããç çå»ã骚é«æ€æ»ã®æšæ¬ã芳å¯ãã
æ ¢æ§éªšé«æ§çœè¡ç ã®èšºæãè¡ããŸããããã«ç çå»ã¯ãä»å
çæè²äœç°åžžã®æç¡ããæ ¢æ§éªšé«æ§çœè¡ç ã现åé¡ããŸãã
ãã®éãPCR*æ³ã FISH*æ³ã¯ãã£ã©ãã«ãã£ã¢æè²äœ*ãå
å®ããããã«äœ¿çšããŸãã
![Page 9: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/9.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 8
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
é©åãªæ²»çãåããã«ã¯äœãéèŠãïŒ
æé©ãªæ²»çãè¡ãã«ããã£ãŠãå»åž«ã¯æ£è ãããšçœè¡ç ã®äž¡é¢ã«ãã
ãŠãå€ãã®åé¡ãèæ ®ããå¿ èŠãããã§ãããã
æ£è ããã«é¢é£ããæ å ± æ£è ããå人ã®ç æŽã»æ²»çæŽ
å»åž«ã«ãã蚺å¯*ã®çµæ
äžè¬çãªå¥åº·ç¶æ
骚é«ç§»æ€*ã®ããã®ã¿ã€ãã³ã°æ€æ»ãæ ¢æ§éªšé«æ§çœè¡ç ã«å¯Ÿã
ãæšçæ²»ç*ãéçºããã以åã¯ãæ²»çã®ç¬¬äžéžæã¯éªšé«ç§»æ€
ã§ãããçŸåšã§ããæ ¢æ§éªšé«æ§çœè¡ç ã®æ£è ããã®äžã«ã¯éªšé«
移æ€ãå¿ èŠãªæ¹ãããŸãããããã¯ãããŠãååæšçæ²»çã«ããå¹æãåºããç æ°
ãé²è¡ããå Žåã«éããŸãã骚é«ç§»æ€ã¯ããã现èãå«ãã æ£è ããèªèº«ã®éªšé«ãã
誰ãã®å¥åº·ãªéªšé«ãçšããŠçœ®ãæããŸãã骚é«æäŸè ïŒãããŒïŒã®å ç«ã·ã¹ãã *ã«
ãã£ãŠæ£è ããã®èº«äœããã¡ãŒãžãåããïŒç§»æ€ç*察宿䞻ç ãšããŠç¥ãããç¶æ ïŒ
ã®ãé²ãããããããŒãšæ£è ããããé©åããããã©ãããçµç¹ã¿ã€ãã³ã°æ€æ»ã
ããªããŠã¯ãªããŸãããããã¯ãããçœè¡ç*æåïŒHLAïŒãšåŒã°ããç¹ç°çãªã¿ã³
ãã¯è³ª*ããæ£è ãããšãããŒã®éã§ã©ããããé¡äŒŒããŠãããã®åºŠåãã«ãã£ãŠæ±º
ãŸããŸããé©åãã骚é«ãèŠã€ãããŸã§ã¯æ°ã¶æãèŠãããããåãã£ãŠæ£è ãã
ã® HLA ã¿ã€ããç¥ã£ãŠããããšã¯æçšã§ãããããŒã«ãªãå¯èœæ§ã®ããå åŒãå§åŠ¹
ã® HLA ã¿ã€ãã³ã°æ€æ»ããŸãè¡ã£ãŠãããã»ããããã§ããããããå åŒãå§åŠ¹ã
ãé©åãããªããã°ãéè¡çžè ã®éªšé«æäŸè ãæ€çŽ¢ããããšã«ãªãã§ãããã
çœè¡ç ã«é¢ããæ å ±
ç æãäºåŸ*ãšãªã¹ã¯åé¡ ã²ãšã€ã®èåšããïŒä¹³æ¿ã«ã§ããä¹³ãããåç«è ºã«ã§ããåç«è ºãããªã©ã®ããã«ïŒçºçã
ãŠãåºãã£ãŠããïŒè»¢ç§»*ïŒãããªãä»ã®çš®é¡ã®ãããšã¯ç°ãªããçœè¡ç ã®æ£è ããã®ãã
现èã¯ã蚺æãããæç¹ã§ã埪ç°è¡æµã«ããå šèº«ã«æ£ãã°ãåºãã£ãŠãããšèããããŠããŸ
ãããã®ãããªçç±ã§ãçœè¡ç ã®äºåŸã¯ä»ã®ããã®ããã«ç æ°ã®åºããã®ç¯å²ã«ãã£ãŠæ±ºã
ããããã®ã§ã¯ãããŸãããç æ°ã®æ®µéã¯ãæ ¢æ§*æã移è¡æãæ¥æ§*[blastic]æãããªãã¡
æ¥æ§è»¢åãããªã 3 ç æã«ãã£ãŠå®ããããŠããŸãã倧å€æ°ã®æ£è ããã¯æ ¢æ§æã§èšºæã
ããŸãããããæ«æ¢¢è¡ãŸãã¯éªšé«ã«ãããèœçã®å²åã 15-29%ã«å¢å ããããæ«æ¢¢è¡æ¶²
äžã®å¥œå¡©åºç*ã 20%ãè¶ããããè¡å°æ¿*ãéåžžã«äžæãããïŒæ²»çã®çµæãšããŠã§ã¯ãª
ãïŒäœäžãããããã£ã©ãã«ãã£ã¢æè²äœ*ã«å ããŠã¯ããŒã³æ§ã®ããç°åžžãèªããããå Ž
åã«ã¯ã移è¡æãšèšºæãããŸããæãé²ãã ç æã¯ã骚é«ãæ«æ¢¢è¡äžã®èœçãå°ãªããšã
30%ã«å¢å ããæ¥æ§è»¢åã§ãã
![Page 10: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/10.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 9
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
移è¡æ æ¥æ§æ
èœç[Blast cells]* 15 â 29% ⥠30%
奜塩åºç* > 20% /
è¡å°æ¿æ°** < 100 x 109/L æ²»çã«é¢ä¿ãªã /
CCA / Ph+ ãã /
骚é«ä»¥å€ãžã®æµžæœ€+ / ãã
* æ«æ¢¢è¡ãŸãã¯éªšé«ã«ãããŠ
CCA / Ph+= ãã£ã©ãã«ãã£ã¢æè²äœéœæ§çŽ°èã«ã¯ããŒã³æ§ã®ããæè²äœ*ç°åžžãä»å ãã
ãŠããç¶æ
+èèãšèŸèãé€ãããªã³ãç¯*ãç®èãäžæ¢ç¥çµ(CNS*)ã骚ãèºãå«ãŸããã
ç¡æ²»çã®å Žåãæ ¢æ§*æã® CML ã®æ£è ãã㯠3ïœ5 幎ã§ç§»è¡æã«é²è¡ããã§ãããã移è¡
æãšèšºæãããæ£è ããã®ç¡æ²»çã§ã®çåæéäžå€®å€ã¯ 4ïœ6 ãæã§ããããæ¥æ§è»¢å
[blast* crisis]ãçããå Žåã«ã¯ãç¡æ²»çã§ã®çåæéäžå€®å€ã¯ 2ïœ4 ã¶æãšãçåã¯ãã
ã«éãããŸãã
æ£è ããã®äºåŸ*ã¯ãæ£è ããã®ç¹åŸŽïŒèŸèã®å€§ããã¯ãã¡ããã奜塩åºç*ã®å²åãå«ã¿ãŸ
ãïŒã«ãã£ãŠç確ã«äºæž¬ãããŸããæ²»çãžã®åå¿æ§ãšçåã®å¯èœæ§ãäºæž¬ãããæ£è ããã
ç æ°ã®ç¹åŸŽãçšããå€é ç®ã®è©äŸ¡ã·ã¹ãã ãéçºãããŠããŸããææ°ã® EUTOS ãªã¹ã¯ã¹
ã³ã¢ã§ã¯ã5 幎ã®ç¡å¢æªçåçã¯ãäœãªã¹ã¯çŸ€ã®æ¹ãé«ãªã¹ã¯çŸ€ã«æ¯ã¹ãŠææã«è¯å¥œ
ïŒ90% 察 82%ïŒã§ããããå šçåçã§ã¯æ£åžžã®å¥åº·ãªéå£ã«æ¯ã¹ãŠãããã«äœãã ãã§
ããã
![Page 11: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/11.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 10
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ²»çã®éžæè¢ãšããŠäœãããã®ïŒ
æ²»çã¯æ ¢æ§éªšé«æ§çœè¡ç ãæ²»çããã»ã³ã¿ãŒæ©é¢ãšå€ãã®å°éé åã
蚺çããïŒéåŠçæ²»ç*ïŒå°éæ©é¢ã§ã®ã¿è¡ãããŸããæ²»çã¯èšåºè©Šéš
*ã®åœ¢åŒã§è¡ãããããšãå¿ èŠãªå ŽåããããŸãã
æ ¢æ§éªšé«æ§çœè¡ç ã®æ²»çã¯èšºææã®ç æ°ã®ææã«åºã¥ããŠãæ£è ãã
å人ã«åãããŠè¡ãããŸããåºåœ¢è «çãšã¯ç°ãªããå€ç§çåé€ãšæŸå°
ç·æ²»ç*ã¯æ ¢æ§éªšé«æ§çœè¡ç ã®æ²»çã«ãããŠãäžè¬çã«ã¯åœ¹ã«ç«ã¡ãŸã
ãã
æ ¢æ§ïŒæã®æ ¢æ§éªšé«æ§çœè¡ç ã®æ²»ç
åè¿°ã® 9 çªãš 22 çªã®æè²äœè»¢åº§ã®å€ç°ã¯ãããã·ã³ãããŒãŒã®å€ç°ãåŒãèµ·ãããŸãã
ä»æ¥ã§ã¯ãããããæ£è ããã¯ãŸããBCR-ABL*ããã·ã³ãããŒãŒãšããŠç¥ããããå€ç°
ãã*ããã·ã³ãããŒãŒ*ã«å¯Ÿããé»å®³è¬ã«ãã£ãŠæ²»çãåããŸããã€ã³ã¿ãŒãã§ãã³*ãã
ãããã·ãŠã¬ã¢*ãªã©ã®ãã®ä»ã®è¬å€ã¯ãåææ²»çã«ãããŠã¯ããŸã圹ã«ç«ã¡ãŸããããã
ããã·ãŠã¬ã¢ã¯ãã现èã®éãšçœè¡ç*ãéããã«æžããããã«äœ¿ãããŠããŸããã€ããã
ã*ã¯ç¬¬äžäžä»£ã®çµå£ããã·ã³ãããŒãŒé»å®³è¬*ã§ããã®è¬ãæçšããããšã«ããçŽ 90%ã®
æ£è ããã¯å šçåæéã§ã¿ããš 8 幎ã¯çåããããšãã§ãããšãããŠããŸããããµããã*
ãããããã*ã®ãããªç¬¬ 2 äžä»£ã®ããã·ã³ãããŒãŒé»å®³è¬ããŸãã蚺ææã®å šãŠã®æ ¢æ§éªš
é«æ§çœè¡ç ã®æ£è ããã«å¯ŸããŠèæ ®ãããŸããèšåºè©Šéš*ã§ãããããèšç»ãããŠããå Žå
ããé節ãªå¯äœçšãèµ·ãã£ãå Žåãã®ãããŠã¯ãæ£è ããã¯ã€ãããããããµãããããã
ãã¯ãããããã®å æãéäžã§æ¢ããããšã¯ããããã§ããŸããããããã®è¬å€ã¯ãã€ãŸã§
ã飲ã¿ç¶ããŸããéäžã§ããããšãæ ¢æ§éªšé«æ§çœè¡ç ã®åçº*ãé²è¡*ã«ã€ãªããããã§ãã
æ ¢æ§éªšé«æ§çœè¡ç ã®æ²»çãå§ããåŸã¯ãæ£è ããã¯æ²»çå¹æã®å€å®ã®ããã«å®æçã«è©äŸ¡ã
åããå¿ èŠããããŸããæ²»çãžã®åå¿ãè©äŸ¡ããããšã¯ãæ²»çã«ãã£ãŠååãªå¹æãåŸãã
ãŠããããè¬å€ã®æäžéãå¢ãããããŸãã¯ä»ã®æ²»çã«åãæ¿ããå¿ èŠããããã©ãããå€
æããã®ã«éèŠã§ããæ²»çã¯ç¡æéã«ç¶ããããåçºã¯ã»ãšãã©ã®æ£è ããã«ãããŠæ²»çã®
äžæã«ãã£ãŠèµ·ãããããç æ°ã®ç¶æ ããã£ãããšç£èŠããŠããããšããšãŠãéèŠã§ããã
ãšãæ²»çã«ããè³é©å¥å¹[optimal response]ãåŸãããŠãããšããŠããæœåšçãªåçº*ãã¿
ã€ããŠæ²»çãè¡ãããã«ãç¶ç¶ããŠç£èŠããŠããããšãå¿ èŠã§ããè³é©[optimal]ãæºè³é©
[suboptimal]ã倱æ[failure]ãšãã£ãæ ¢æ§éªšé«æ§çœè¡ç ã«å¯Ÿããç¹æã®å¹æå€å®ã®ããã
ã¯ãé©åãªè¬å€ã®å¢éãæ²»çæ³ã®å€æŽã®æéãšããŠç¢ºç«ãããŠããŸãã
æ²»çå¹æå€å®ã¯äžèšã®éããè¡æ¶²åŠçå¯è§£*ã现èéºäŒåŠçå¯è§£*ãååçç©åŠçå¯è§£*ã® 3
段éã®å¹æã«ããšã¥ããŠè¡ãããŸãã
è¡æ¶²åŠçå¯è§£*
o è¡æ¶²åŠçå¯è§£ã®è©äŸ¡ã®ããã«ã¯ãæ²»çã®éå§ãã 2 é±éæ¯ã«æ«æ¢¢è¡ã®çœè¡ç
*æ°ãšè¡å°æ¿*æ°ã確èªããå¿ èŠããããŸãã
![Page 12: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/12.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 11
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
o è¡æ¶²åŠçå®å šå¯è§£*ãšã¯ãäžèšã®é ç®ãæºãããå ŽåããããŸãã
å šçœè¡çæ° C <10Ã109/lïŒè¡æ¶² 1 ãªããã«ããã 10Ã109 åæª
æºïŒ
çœè¡çã®ãã¡ã幌è¥ãªé¡ç²ç*ããªãããšã奜塩åºç*ã 5%æªæºã§ã
ãããš
è¡å°æ¿æ°<450Ã109/lïŒè¡æ¶²ïŒãªããã«ããã 450Ã109 åæªæºïŒ
èŸèã觊ç¥ããªãããš
现èéºäŒåŠçå¯è§£ (CgR)*
o 现èéºäŒåŠ*çæ€æ»ã¯ããã·ã³ãããŒãŒé»å®³è¬*ã«ããæ²»çãéå§ãã 3 ã¶æ
åŸã6 ã¶æåŸã12 ã¶æåŸã18 ã¶æåŸã«è¡ãããå¿ èŠããããŸãã现èéºäŒ
åŠçå®å šå¯è§£ãåŸããããŸã§ã¯ãå°ãªããšã 6 ã¶ææ¯ã«æ€æ»ãç¹°ãè¿ãè¡ã
ã»ããããã§ãããã
o 现èéºäŒåŠçå®å šå¯è§£(CCgR)ã¯ãåè£æ*ã®æè²äœ*æ€æ»ã«ãã£ãŠãã£ã©ãã«
ãã£ã¢æè²äœ*ãæ€åºã§ããªããªãããšãšå®çŸ©ãããŠããŸãã
o 现èéºäŒåŠçéšåå¯è§£(PCgR)ã¯ãåè£æã®æè²äœæ€æ»ã«ãã£ãŠãã£ã©ãã«ã
ã£ã¢æè²äœ*ã 1%ã35%ååšããããšãšå®çŸ©ãããŠããŸãã
ååçç©åŠçå¯è§£*
o ååçç©åŠçå¯è§£ã®è©äŸ¡ã¯ãBCR-ABL/ABL ç°åžžã®å®éç PCR æ€æ»ã«ãã£ãŠ
è¡ãããŸãã
o ååçç©åŠçæ€æ»ã¯ãååçç©åŠç倧å¯è§£*ãåŸããããŸã§ã¯ãå°ãªããšã 3
ã¶ææ¯ã«ç¹°ãè¿ãè¡ãã»ããããã§ãããã
o ååçç©åŠç倧å¯è§£ã¯ãPCR ã®çµæåœéææšã§ BCR-ABL/ABL ã 0ã
o 10%æªæºã§ããããšãšå®çŸ©ãããŠããŸãã
现èéºäŒåŠçå®å šå¯è§£ãšååçç©åŠå®å šå¯è§£ã®äž¡æ¹ãéæãããã现èéºäŒåŠçæ€
æ»ã¯ 12 ã¶ææ¯ã«ãPCR ã«ããååçç©åŠçæ€æ»ã¯ 6 ã¶ææ¯ã«è¡ãå¿ èŠããããŸãã
è³é©å¥å¹[optimal response]ãéæããæ£è ããã¯ãçŸåšæäžäžã®ã€ãããã*ã第 2 äž
代ã®ããã·ã³ãããŒãŒé»å®³è¬*ã«ããæ²»çãç¶ç¶ããã»ããããã§ãããããã®æ£è ããã
ã¡ãæ²»çãäžæããå Žåã¯ãèšåºè©Šéš*ã®èšå®ã§ã®ã¿è¡ãããããšãæãŸããã§ãã
æºè³é©å¥å¹[suboptimal response]ããåŸãããªãã£ãæ£è ããã¯ãçŸåšå æããŠããã
ãã·ã³ãããŒãŒé»å®³è¬ã®å¢éããããçŸåšã€ãããããå æäžã§ããã°ã第 2 äžä»£ã®ãã
ã·ã³ãããŒãŒé»å®³è¬ãžã®å€æŽãèæ ®ããå¿ èŠããããŸãã
ã€ããããã§å¥å¹ãåŸãããªãã£ãæ£è ããã§ã¯ãããµããã*ãããããããªã©ã®ç¬¬ 2 äž
代ã®ããã·ã³ãããŒãŒé»å®³è¬ãžã®æ²»çã®å€æŽãããå¿ èŠããããŸããæè¿ã§ã¯ããã®ä»ã®ç¬¬
2 äžä»£ã®ããã·ã³ãããŒãŒé»å®³è¬ïŒãã¹ãããïŒãã¢ã¡ãªã«åè¡åœã§èªå¯ãããŠããŸããã
ãã·ã³ãããŒãŒé»å®³è¬ã®ãããããããŸããT315I å€ç°*ãšåŒã°ããç¹ç°çãªå€ç°ããã€æ ¢
æ§éªšé«æ§çœè¡ç ã«å¯ŸããŠãã¢ã¡ãªã«åè¡åœã§èªå¯ãããŸãããããã·ã³ãããŒãŒé»å®³è¬ã«ã¯
å±ããªã omacetaxine ãšããè¬å€ããŸããããã·ã³ãããŒãŒé»å®³è¬ã«æµææ§ã®æ ¢æ§éªšé«æ§
çœè¡ç ã®æ²»çã«å¯ŸããŠãã¢ã¡ãªã«åè¡åœã§æè¿èªå¯ãããŸãããã€ããããã®å¢éã¯ãç æ°
ãæªåããŠããæã«ã¯æå¹æ§ããªãããã§ããå¹æãåŸãããããšãšããã®å¹æã®æç¶æé
ã¯ãæ£è ãããå皮骚é«ç§»æ€*ãåãããã©ãããèããéã«ãéèŠãªå€æææãšãªããŸãã
![Page 13: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/13.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 12
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
移è¡æãŸãã¯æ¥æ§è»¢åïŒæã®æ ¢æ§éªšé«æ§çœè¡ç ã®æ²»ç
ãããã®ææã«ãããŠã¯ãã©ã®æ²»çéžæè¢ãæè¯ãã決ããããã®æ ¹æ ã¯ãããéå®ãããŸãã
ããã·ã³ãããŒãŒé»å®³è¬ã«ããæ²»çã¯ãããã·ã³ãããŒãŒé»å®³è¬ã«ããæ²»çããŸã åããŠããªã
æ£è ããã«å¯ŸããŠã¯å§ããããšãã§ããŸãããã§ã«ããã·ã³ãããŒãŒé»å®³è¬ã«ããæ²»çãåããŠ
ããæ£è ããã«ã¯ãä»ã®ããã·ã³ãããŒãŒé»å®³è¬ãžã®å€æŽãããŸãã¯ååŠçæ³ãèæ ®ãããŸãã
ããããªããããããã®éžæè¢ã¯ãããçšåºŠã®æéããå¹æããããŸããã
ãããã®æ£è ããã«ã¯ãå皮骚é«ç§»æ€*ãäŸç¶æãæ ¹æ ã®ããæ²»çéžæè¢ã§ãããèæ ®ãããå¿
èŠããããŸããããã¯ä»äººã®éªšé«å¹¹çŽ°è*ãæ£è ããã«ç§»ãæ¿ããäœæ¥ã§ããæ£è ããã®çœè¡ç*
ãèµ€è¡ç*ãè¡å°æ¿*ã¯ããããŒã®çŽ°èã§çœ®ãæããããŸãããããŒã®çŽ°èã¯ãã¹ãŠãæ£è ããèª
身ã®è¡æ¶²ã®äžéšã«ãªããŸãããããŒã®çŽ°èã¯æ£è ããã®èº«äœã«ãšã£ãŠãæªç¥ã®ãã®ã§ããããã
ããŒã®çŽ°èã¯æ£è ããã®çŽ°èãç°ç©ãšèªèããããšãã§ãããã®çµææ£è ããã®çŽ°èãæ»æãã
ããšã«ãªããŸãïŒããã¯ç§»æ€ç察宿䞻ç (GVHD)ãšããŠç¥ãããŠããŸãïŒãGVHD ã¯å žåçã«
ã¯ããããŒã®ç§»æ€ç*ã«å«ãŸãã T 现è*ãæ£è ããã®ç®èãæ¶å管ïŒå£ãèãè žïŒãèèã«æ¥
觊ããããšã«é¢ä¿ããŸãããããã®çµç¹ã¯éäž»èŠçµç¹é©åæåïŒãçºçŸããŠããŸãããäž»èŠçµç¹
é©åæåãšå¯Ÿç §çã«ããããŒãšæ£è ã®éã§éäž»èŠçµç¹é©åæåãäžèŽããŠãããã©ããã移æ€å
ã«ããããã確èªããå¿ èŠã¯ãªããšãããŠããŸãããããã®éäž»èŠæåãçºçŸããŠããããšãã
çµç¹ãç°ç©ãšããŠèªèããããšã«ã€ãªãããŸããåæ§ã®éçšã«ãããŠããããŒã®çŽ°èã¯æ£è ãã
ã®çœè¡ç 现èããç°ç©ãšããŠèªèããç Žå£ããŸããããã骚é«ç§»æ€ã®äž»ããæçãªå¹æã§ãïŒã
ãã¯ç§»æ€ç察çœè¡ç å¹æïŒGVLïŒãšããŠç¥ãããŠããŸãïŒã骚é«ç§»æ€ã¯çœè¡ç ãå®å šã«æé€ãã
æ£è ãããæ²»çãããå¯èœæ§ãæã£ãŠããŸãã
å皮骚é«ç§»æ€*ã¯ãããã®ç æã®æ ¢æ§éªšé«æ§çœè¡ç ã«å¯ŸããŠãå¯äžã®æ²»çãç®æããæ²»ç*ãš
ããŠç¢ºç«ããŠããŸãã移æ€ã®åã«ç æ°ã®é²è¡ãã³ã³ãããŒã«ããããçšåºŠã®å¹æãåŸããã
ã«ãæ£è ããã¯èšåºè©Šéš*ã第 2 äžä»£ã®ããã·ã³ãããŒãŒé»å®³è¬*ãåŸæ¥ã®çŽ°èå·å®³æ§*è¬å€
ã«ããååŠçæ³*ãæ€èšããå¿ èŠããããŸãã
![Page 14: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/14.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 13
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ²»çæµææ§ã®å Žåã®æ²»ç
ãã®ç æ°ã¯ããã·ã³ãããŒãŒé»å®³è¬*ã«æµææ§*ãšãªãããšããããŸããç æ°ã®æµææ§ã¯
BCR-ABL*ã®å€ç°*ã«ãã£ãŠãç æ°ã®é²è¡ãšããŠãããããŸããç æ°ãé²è¡ããŠãè¬å€ã®å¢
éãä»ã®ããã·ã³ãããŒãŒé»å®³è¬ãžã®è¬å€ã®å€æŽãããæã«ãããã·ã³ãããŒãŒã«å¯Ÿããæ²»
çãžã®æµææ§ã«ã€ãªããå€ç°ã調ã¹ãããšãéèŠã§ããè¬ã決ãããããšãã飲ããŠããªã
ããšããè¬å€ä»£è¬*ãåé¡ãšãªãé ããŸãã«ããããã®éã¯ã€ãããã*ã®è¬å€è¡äžæ¿åºŠã枬
å®ããããšãã§ããŸããçœè¡ç 现èã T315I å€ç°ãšåŒã°ããç¹ç°çãªå€ç°ã瀺ããå Žåã¯ã
æ£è ããã¯ããããããšããããããã·ã³ãããŒãŒé»å®³è¬ã«ãã£ãŠæ²»çãåããããšãã§ã
ãŸãã
ããã·ã³ãããŒãŒé»å®³è¬ïŒãããŸã䜿ããªãæ£è ããã®æ²»çïŒ
ç®èã®ã²ã©ã湿ç¹ãã²ã©ãæµ®è «ïŒè¶³ã®ããã¿ïŒãèžæ°ŽãããŸããªã©ã®éãå¯äœçšãã第ïŒäž
代ã®ããã·ã³ãããŒãŒé»å®³è¬ã«ãã£ãŠèµ·ãã£ãæ£è ããã¯ããŸãã¯ç¬¬ïŒäžä»£ã®ããã·ã³ãã
ãŒãŒ*é»å®³è¬*ã§æ²»çãããã®ãããã§ãããã第ïŒäžä»£ã®ããã·ã³ãããŒãŒé»å®³è¬ãããŸã
䜿ããªãæ£è ããã®å€ãã¯ã第 2 äžä»£ã®ããã·ã³ãããŒãŒé»å®³è¬ã§ãå¯äœçšãèµ·ããããš
ãªãããŸãæ²»çããããšãã§ããŸãã第 2 äžä»£ã®ããã·ã³ãããŒãŒé»å®³è¬ã¯ãå¯äœçšã®ãª
ã¹ã¯ãæžããããã«ãæå¹æ§*ãæãªãããšãªãéãæžããããšãã§ããŸãã3 çš®é¡ã®ãã
ã·ã³ãããŒãŒé»å®³è¬ãããŸã䜿ããªãæ£è ããã«ãšã£ãŠããªãã»ã¿ãã·ã³[omacetaxine]*
ãšããæ°ããæ²»çè¬ããæå¹ãã€å®å šã§ããããšãæè¿ããã£ãŠããŸããããŸãã§ã¯ãããŸ
ãããããããããã·ã³ãããŒãŒé»å®³è¬ãããŸã䜿ããªãæ£è ããã§ã¯ãå åŒãè¡çžã§ãªã
ãããŒããã®éªšé«ç§»æ€ãèããå¿ èŠããããŸãã
ç æ°ã«ããçç¶ãæ²»çã«ããå¯äœçšã®ãããŒãžã¡ã³ã
çœè¡ç ãšããã«å¯Ÿããæ²»çã¯ãäžç¢ãåãæ°ãååãè±æ¯ã掻åãé£æ¬²ã®äœäžãææçãªã©
ã®éãå¯äœçšãåŒãèµ·ããããšããããŸãããããã£ãå¯äœçšã«å¯ŸããŠã¯å¹æçãªæ²»çæ³ã
ãããæ£è ããã¯ãããã£ãåé¡ã®ããã€ãã¯è§£æ±ºã§ãããšæåŸ ããŠããã§ãããã
![Page 15: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/15.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 14
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ²»çãéå§ããã次ã¯ã©ãããã?
ä»æ¥ãCML ã®æ£è ããã¯ããã·ã³ãããŒãŒé»å®³å€*ã«ããç涯ã«ããã£
ãŠã®æ²»çãå¿ èŠã§ããæ²»çãäžæããããšãã§ããã®ãããããŠæ²»çã
äžæããããšãèš±ãããã®ã¯ã©ããªæ£è ããã§ããã®ãã調ã¹ãããã®
ç 究ãé²è¡äžã§ããæ²»çã®äžæã¯èšåºè©ŠéšïŒæ²»éšïŒ*以å€ã§ã¯å§ããããŸ
ããã
ã©ãããŠå»åž«ã«ãããã©ããŒã¢ãããå¿ èŠã§ãã©ã®ãã
ã«çµé芳å¯ããã®ãïŒ
æ²»çãäžæŠéå§ããããšãå»åž«ã¯æ¬¡ã®ãããªç®çã§ãã©ããŒã¢ãã*ãææ¡ããã§ããã :
é²è¡ãåçºãçœè¡ç ã«æ»ãå¯èœæ§ãã§ããã ãæ©æã«æ€åºããã
æ²»çã«ããå¯äœçšãè©äŸ¡ããŠããããæ²»çããã
粟ç¥çãªãµããŒãããããæ©äŒããæ®æ®µã®ç掻ã«ããæ©æã«åŸ©åž°ããããã®æ å ±ã
æäŸããã
å»åž«ã«ãããã©ããŒã¢ããã®å蚺ã«ã¯æ¬¡ã®ããšãå«ãŸããŸã:
å蚺ããçç¶ã®èããšãã蚺å¯ã
æ¯åã®å šè¡çç®å®ïŒè¡ç®ïŒã
æ²»çãäžæåã®å Žåããåå äžæã®è¡å°æ¿æžå°*ãä¿¡é Œã§ããååéºäŒåŠçãªæ€æ»ã
åŸãããªãå Žåã«ã®ã¿ã骚é«çæ€æ€æ»ãç¹°ãè¿ãããŸãã
äžè¬çã«æ²»çéå§åŸ 3 ãæç®ãã现èéºäŒåŠç*ãªæ€æ»ãã现èéºäŒåŠçå®å šå¯è§£*ã«å°é
ããããšã確èªããããŸã§ 6 ãæããšã«ç¹°ãè¿ãããŸãããããŠãååéºäŒåŠç倧å¯è§£ã«
å°éãããŸã§ 3 ãæããšã« PCR*æ€æ»ãè¡ãããŸããã²ãšãã³çŽ°èéºäŒåŠçå®å šå¯è§£ã«å°
éããããšã確èªãããã°ã现èéºäŒåŠçãªæ€æ»ã¯ 12 ã¶æããšã«å§ããããŸãããååéº
äŒåŠçæ€æ»ãå©çšã§ãããã€ä¿¡é Œã§ãããã®ã§ããã°å¿ èŠãããŸãããäžæŠãååéºäŒåŠç
倧å¯è§£ã«å°éããããšã確èªãããã°ãååéºäŒåŠçæ€æ»ã¯å°ãªããšã 6 ãæããšã«å§ã
ãããŸããããããªã¹ã¯åé¡ãé«ãªã¹ã¯çŸ€ã®å ŽåããŸãã¯ãæ²»çã®å¹æãäžååã§ãã£ãå Ž
åã«ã¯ãããé »ç¹ã«æ€æ»ãããããšãå§ããããã§ããããBCR-ABL å€ç°*æ€æ»ã¯ãæ²»ç
ãäžæåã®å Žåããå¹æãäžååã®å Žåã«ã®ã¿ææ¡ããããã®ã§ãã
æ®æ®µã®ç掻ã«æ»ãããã«
çœè¡ç åçºã®å¯èœæ§ãå¿é ããªããç掻ããããšã¯ã€ããããšã§ããçŸåšç¥ãããŠããç¯å²
ã«ãããŠã¯ãåçº*ã®ãªã¹ã¯ãæžããç¹å¥ãªæ¹æ³ã¯ååšããŸããããããã®ãã®ããæ²»çã®
çµæãšããŠæ®æ®µã®ç掻ã«æ»ãããšãé£ãã人ãã¡ãããŸãã身äœã€ã¡ãŒãžãæ§çèœåãç²åŽã
ä»äºãææ ãç掻ã¹ã¿ã€ã«ã«é¢é£ããçåããæžå¿µããããããããŸããããããã®çåãã
芪é¡ãå人ãä»ã®æ£è ããå»åž«ããšæèŠã亀ããããšã¯ã圹ã«ç«ã€ã§ãããã粟ç¥è «çå»ãš
ã®çžè«ãµãŒãã¹ãé»è©±ã«ããæ å ±ãµãŒãã¹ã ãã§ãªããäŸãã°ãæ²»çã«ãã圱é¿ã管çãã
æ¹æ³ãã¢ããã€ã¹ãããªã©ã®ãæ£è å£äœããã®ååã¯ãå€ãã®åœã ã§åŸãããã§ãããã
![Page 16: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/16.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 15
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
è¬ãæçšããããšã¯ã©ãã ãéèŠãªã®ãïŒ
å®éã«åããæ²»çã ãããå¹æãçºæ®ãåŸãã®ã§ããåŠæ¹ãããããã«ãè¬ãæçšããããš
ããšãŠãéèŠã§ãã
CML ã®æ£è ããã«ãããŠããè¬ã®æè¬ç¶æ³ãææã«åœ±é¿ãäžããããšãç 究ã§æããã«ã
ããŠããŸããç¹ã«ãCML ã®ããã«å æè¬ã§æ²»çãããå Žåã«ã¯ãåŠæ¹ããããè¬ãå æã
ãããšã¯ããããŠãæ£è ããã®èªå·±è²¬ä»»ãšããŠä»»ãããŠããŸããæå³çã«ããããã¯æ°ã¥ã
ãã«æè¬ãå®ãããªãããšã¯ãæ²»çã®æåãå¹æã®ç¶æã«é倧ãªåœ±é¿ãäžããŸããæè¬éµå®
ã®çšåºŠã¯ãå ¥é¢æ²»ççãšåæ§ã«ãåçºçãå¥å¹çãšåŒ·ãé¢é£ãããããšããCML æ£è ãã
ã®ç 究ã§æããã«ãããŠããŸãã 10 é äžïŒé ãæè¬ããªãã£ãã ãã§ããå¯è§£
[remission]*çã«ææã«åœ±é¿ãäžããããšãããã£ãŠããŸãã
ããçœè¡ç ãé²è¡ããŸãã¯åçºãããã©ãããã®ãïŒ
æ ¢æ§*æãã移è¡æãæ¥æ§[blastic]*æã«å€åãããªã©ãçœè¡ç ãé²è¡ããå Žåã«ã¯ãç æã®
å¢æªãåçºãšåŒã°ããŠããŸããæ²»çã¯ãæ£è ããã®å¹Žéœ¢ããããŸã§åããæ²»çå 容ãã骚é«
移æ€*ãå¯èœãã©ããã«ãããŸããç æ°ã®æ®µéã«å¿ããŠãå ·äœçãªæšå¥šãããæ²»çãæ€èšã
ããŸãã
移è¡æãæ¥æ§è»¢åã®æ£è ãããT315I å€ç°*ãèªããããæ£è ããã¯ãããå åŒãå§åŠ¹ãé
è¡çžè ã®ãããŒãåŸãããã®ãªãã°ã第 2 äžä»£ã®ããã·ã³ãããŒãŒé»å®³å€*ã«ããæ²»çå¹æ
ãåŸãããåŸã«ãæ²»çã®æ©äŒãåŸãããå¯äžã®æ²»çãšããŠéªšé«ç§»æ€ãè¡ãããšãå§ããããŸ
ãã骚é«ç§»æ€åŸã«åçºããæ£è ããã¯ãéåžžã2 åç®ã®ç§»æ€ã¯èããŸããã代ããã«ããã
ã·ã³ãããŒãŒé»å®³å€ãšäœµçšããŠãããŒãªã³ãç茞泚*ãæœè¡ããããŸãã¯èšåºè©ŠéšïŒæ²»éšïŒ*
ã«ç»é²ããããšãã移æ€åŸã«åçºããæ£è ããã«ãšã£ãŠå¥œãŸããæ²»çéžæè¢ã§ãã
æ²»éšã¯èæ ®ããã»ãããããïŒ
ããã·ã³ãããŒãŒé»å®³å€*ãå«ãã çŸåšã®æšæºæ²»çã«ãããCML ãšèšºæãããæ£è ããã®äº
åŸã¯è¯å¥œã§ãããŸãã«ãçŸåšã®æé©ãªæ²»çã«ãé¢ããããç æ°ã®é²è¡ãèªããããŸãããã®
ãããªå Žåã«ã¯ãäºåŸã¯äžè¯ã§ãããæ²»éš*ãå«ãå¥ã®æ²»çãèæ ®ããå¿ èŠããããŸããã
ã®ãããªçç±ã§ãå»åž«ãç§åŠè ãã¡ã¯æ°ããæ²»çæ³ãç 究ããŠããŸããèŠèŸŒã¿ã®ããæ²»çæ³
ã¯ãæ¿èªãããŠãã¹ãŠæ£è ããã«æäžãããåã«ããŸãæ²»éšãšããŠè©Šãããå¿ èŠããããŸãã
æ²»éšã¯ãäžè¬çã«å©çšã§ããåã«ãæ°ããæ²»çãåããæ©äŒãæäŸããŠãããŸããäžæ¹ã§ã
ãã®ãããªæ°ããæ²»çæ³ã¯ãæªç¥ã®å¯äœçšããããªã©ãããã€ãã®ãªã¹ã¯ã䌎ããŸããæ²»éš
ã«ã¯ããã®ããã«è¯ãé¢ãšãæªãé¢ããããããããªãã«ãšã£ãŠæ²»éšããµãããããã©ãã
ã«ã€ããŠãæ åœå»åž«ã«çžè«ããããšã倧å€éèŠã§ãã
![Page 17: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/17.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 16
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
ã©ã㧠CML æ£è æ¯æŽå£äœãèŠã€ããããã®ãïŒ æ£è æ¯æŽå£äœ[patient advocacy groups]*ã¯ãä»ã® CML æ£è ãããšé£çµ¡ãåããç æ°ã
ãã詳ããåŠã¶ã圹ç«ã€æ å ±ã確èªãããã»ã«ã³ããªãããªã³ã®çºã®çµéšã®ããå»åž«ãæ¢ãã
æ²»éš*ãå®æœããŠããèšåºæœèšã確èªããããªã©ã®æ¯æŽãããŠãããŸããããªãã®åœã§æ£è
æ¯æŽå£äœãèŠã€ããã«ã¯ãCML æ¯æŽãããã¯ãŒã¯å£äœã蚪ããŠãã ããã
http://www.cmladvocates.net/members
![Page 18: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/18.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 17
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
çšèªã®èª¬æ
BCR-ABL
ãã£ã©ãã«ãã£ã¢æè²äœ*ïŒ9 çªãš 22 çªæè²äœã®è»¢åº§ãt(9;22)ïŒã¯ã9 çªæè²äœ*äžã®
Abelson murine leukemiaïŒABLïŒéºäŒåãšã22 çªæè²äœäžã® breakpoint cluster
regionïŒBCRïŒéºäŒåã転座ãããã®ã§ã95%ã® CML æ£è ããã®æ«æ¢¢è¡ã骚é«è¡ã®çŽ°è
ããæ€åºãããŸãããã£ã©ãã«ãã£ã¢æè²äœã¯å¶åŸ¡æ©èœã倱ã£ãããã·ã³ãªã³é žåé µçŽ ïŒã
ãã·ã³ãããŒãŒïŒ*ïŒçŽ°èã«ååšããé µçŽ ïŒãã³ãŒãããããã«ãã现èã®äžæ»åã现èå
転ãå¢æ®èœã®äº¢é²ããããŠç°åžžãªçŽ°èæçããããããŸãã
CT ã¹ãã£ã³
èåšã X ç·ã§ã¹ãã£ã³ããã®çµæãã³ã³ãã¥ãŒã¿ãŒã§åŠçããèåšã®ç»åãæ§æãã X ç·æ®åœ±ã
DNA
ããªãã·ãªãæ žé žã®ç¥èªãDNA ã¯éºäŒæ å ±ãäŒãã圹å²ããããŸãã
FISH/èå in situ ãã€ããªãã€ãŒãŒã·ã§ã³
ç çå»*ã«ãã£ãŠè¡ãããéºäŒåãæè²äœ*ã®å€åã確èªããææ³ã§ããFISH ã«ãã£ãŠç¹ç°
çãªéºäŒåãæè²äœã®å€åãèŠã€ããããã®æ£è ããã®çãã©ã®ãããªçš®é¡ã®ãã®ããç¥ã
ããšãã§ããŸãã
PCR/ããªã¡ã©ãŒãŒé£éåå¿
éºäŒåãã³ãŒãããé åã枬å®ããææ³ãç çå»ã¯ãçœè¡ç ã®çš®é¡ãç¹å®ããããã®æçŽã§
ããç¹æã®å€ç°ïŒã³ãŒãé åã®å€åïŒãåå®ããããã« PCR ãçšããŸãã
T 现è
äœå ã«ãããã®ãèªèº«ã®äœçŽ°èã«ç±æ¥ãããã®ãããã以å€ã«ç±æ¥ãããã®ããåºå¥ããã
ãšãã§ããçœè¡ç(ãªã³ãç)ã®ïŒã€ã§ããææ现èãå·å®³ããå ç«ç³»ã§éèŠãªåœ¹å²ãæ ããŸ
ãã
移æ€ç
å¥åº·ãªç®èã骚ããã®ä»ã®äœã®äžéšããæ¡åããçµç¹ã®ããšã瀺ããäœããåãé€ããç å€
éšäœãå·ã€ããçµç¹ã眮ãæããããã«äœ¿çšãããŸãã
ã€ãããã
ã€ããããã¯ããã·ã³ãããŒãŒé»å®³è¬ã§ããããã·ã³ãããŒãŒãç¹ç°çã«é»å®³ããŸãããã
ã·ã³ãããŒãŒã¯å¢æ®ãããã现èã®è¡šé¢ã«å«ãŸããã€ããããã¯ãããã®å容äœã®åããé»
害ããããšã«ãã£ãŠçŽ°èåè£ãã³ã³ãããŒã«ããŸãã
![Page 19: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/19.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 18
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
ã€ã³ã¿ãŒãã§ãã³
ãªã³ãçã«ãã£ãŠç£çãããå ç«çŽ°èéã§æ å ±äŒéãæ ãèçœã§ããçç©åŠçåå¿ä¿®é£Ÿç©è³ª
(ææçãè «ç现èã«å¯Ÿãã身äœã®åå¿ãæ¹åããããšãã§ããç©è³ª)ã§ããã€ã³ã¿ãŒãã§ã
ã³Î±ãβãγãšããã€ãã®çš®é¡ããããéåžžã¯äœå ã§ç£çãããŸãããçããã®ä»ã®çŸæ£ã®
æ²»çã®ããå®éšå®€ã§ãäœãããŠããŸãã
ãªãã»ã¿ãã·ã³
现èã®æé·ãé 延ãããããããã¯æ¢ããäœçšã®ããç 究段éã®æçå€ã®ããšã§ãã
ååŠçæ³
è¬å€ã«ããç现èãæ»æ» ãããè «çã®å¢æ®ãæå¶ããçæ²»çã®äžçš®ã§ãããããã®è¬å€ã¯é
åžžãæ£è ããã®éèå ãžç·©åŸã«æ³šå ¥ãããŸãããçµå£æäžãã§ãããã®ããããŸããçã®å±
åšã«ãã£ãŠãåè¢ãèèïŒèš³è èš»ïŒèåèãéèïŒã«çŽæ¥æäžããããšãã§ããŸãã
å¯è§£
ããã®å åãçç¶ã®æžå°ãŸãã¯æ¶å€±ãéšåå¯è§£ã¯ãå šãŠã§ã¯ãªããããããã®å åãçç¶ã
æ¶å€±ãŸãã¯æžå°ããããšãå®å šå¯è§£ã¯ãããã¯èº«äœã®äžã«ãŸã ãããããããªãããå šãŠã®
ããã®åŸŽåãçç¶ãæ¶å€±ããããšã
ïŒè¡æ¶²ïŒå¹¹çŽ°è
幹现èã¯æ§ã ãªçš®é¡ã®ãæ§ã ãªæé·æ®µéã®çŽ°èã«ååããããšãã§ãããã°ãããæœåšèœå
ãæã£ã现èã§ããå ããŠãå€ãã®çµç¹ã§çµ¶ãéãªã现èãè£å ããå éšä¿®åŸ©ã·ã¹ãã ã®äž
éšãšããŠæ©èœããŸãã幹现èãåè£ãããšãæ°ãã«åè£ãã幹现èã¯ã幹现èã®ãŸãŸã§ãã
ããšããçãèµ€è¡çãè³çŽ°èãªã©ãã£ãšç¹å¥ãªèœåãæã£ã现èã«ååããããšããã©ã¡ã
ãå¯èœã§ãã幹现è㯠2 ã€ã®éèŠãªæ§æ Œãããä»ã®çŽ°èãšã¯åºå¥ããŠèããããŠããŸãã1
ã€ç®ã¯ãããããšãé·ãäžæŽ»åã®åŸã§ãã£ããšããŠãã现èåè£ã®åŸã«èªå·±è€è£œèœåãæã
ããšããããšã2 ã€ç®ã¯ççåŠçããããã¯å®éšçãªç¶æ³äžã§ãçµç¹ãèåšç¹ç°çãªæ©èœã
æã€çŽ°èã«ååããèœåãæãããšããããšã§ããæ¶å管ã骚é«ãªã©ã®èåšã§ã¯ã幹现èã¯
æ¶èããå·ã€ããçµç¹ã修埩ã眮æããããã«ãåžžã«åè£ãç¹°ãè¿ããŠããŸãã
è¡å°æ¿æžå°ç
è¡æ¶²äžã®è¡å°æ¿æ°ãç°åžžã«å°ãªãç¶æ ã
é¡ç²ç
ææçãã¢ã¬ã«ã®ãŒåå¿ãããŠåæ¯ã®éã«åæ³ãããé µçŽ é¡ãå«ãã é¡ç²ïŒå°ããªç²ïŒãæ
ããå ç«çŽ°èã® 1 çš®ã§ãã奜äžçãå¥œé žçãããŠå¥œå¡©åºçã¯é¡ç²çã§ããé¡ç²çã¯çœè¡ç
ã®äžçš®ã§ããé¡ç²çœè¡çãå€æ žå¥œäžçïŒPMNïŒãããŠå€æ žçœè¡çãªã©ãšãåŒã°ããŸãã
èœç (blast)
çœè¡ç 现èã¯ãã°ãã°èœçãšåŒã°ãããããã¯æµè¡äžã«ã¿ãããæ£åžžã®çœè¡ç现èããã倧
ããã§ããèœçã®èŠãæ¹ã¯ãç çåŠè ã«æ£è ããã®çœè¡ç ã®ã¿ã€ããã©ã®ãããªãã®ã蚺æ
ããææãããäžããŸãã
![Page 20: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/20.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 19
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ£è æ¯æŽè ïŒæ£è æ¯æŽå£äœ
å»åž«ãä¿éºäŒç€Ÿãéçšè ãã±ãŒã¹ãããŒãžã£ãŒãæ³åŸå®¶ãªã©æ£è ããã®å¥åº·ã«é¢ãããæ£è
ãããæå©ããã人ã ã®ããšã§ããå¥åº·ãå»çè²»ãæ£è ããã®ç ç¶ã«é¢é£ããäžå©çã解決
ããæå©ããããŸããããã®æ¯æŽå£äœã¯ãããã®æ¯æŽãµãŒãã¹ãæè²ãç 究ã®å¿ èŠæ§ãªã©ã®
ããã®éèŠãªåé¡ã«ã€ããŠã®åçºãããŠããŸãããã®ãããªæ¯æŽè ãå£äœã¯ããæ£è ããã
ãã®å®¶æã®æå©ããããããã«åããŠããŸãã
è¡æ¶²åŠçå¯è§£
è¡ãããæ²»çã«å¯Ÿããæ²»çã«å¯Ÿããå¹æãè¡šãæ¹æ³ã® 1 ã€ã§ããCML ã«ãããŠè¡æž åŠçå¯
解ã¯æ£è ããã®è¡æ¶²äžã«èœçãçœè¡ç 现èãèªãããèŸè «ãæ£åžžåããCML ã«ãã城åã
çç¶ãèªããªããªãç¶æ ã§ãè¡çæ°ç¹ã«çœè¡çãšè¡å°æ¿ã®æ£åžžåãæºãããéã«å®å šïŒè¡æ¶²
åŠçå®å šå¯è§£ããã㯠CHRïŒãšãªããŸãã
è¡å°æ¿
è¡æ¶²ååºã«ãããŠãåºæ¬çãªåœ¹å²ãæ ãå°ããªçŽ°èæçãè¡å°æ¿æ°ãäœãæ£è ããã¯ãé床
ã®åºè¡ã®å±éºã«ããããããé«å€ã®å Žåã¯è¡æ çã®å±éºããããè¡æ 圢æã«äŒŽãè¡ç®¡éå¡ã«
ãããè³åäžãŸãã¯é節ãªç¶æ ã«é¥ãããšããããŸãããŸããè¡å°æ¿ã®æ©èœäžå šã®å Žåãé
床ãªåºè¡ã®å±éºã䌎ãããšããããŸãã
骚é«çæ€
骚ãšéªšé«ã®äžããå°éã®ãµã³ãã«ãæ¡åããææã§ãéåžžã¯è žéªšããè¡ãããŸããç®èã®äž
éšãšéªšã®è¡šé¢ã«éº»é è¬ãçšããŠéº»çºãããŸããããããç¹æ®ãªå¹ ã®åºãéã骚ã®äžã«æ¿å ¥ãã
å転ãããŠéªšé«ãšéªšçµç¹ãéã®äžã«å ¥ããŠæ¡åããŸããæ¡åãã现èãçµç¹ã¯ç çåŠè ã«ã
ã£ãŠæ€æ»ãããŸãããã®æ¹æ³ã¯éªšé«åžåŒãå®æœãããšãã«ãåŒãç¶ããŠè¡ãããŸããç çåŠ
è ã¯ãã®çµç¹ãé¡åŸ®é¡ã§èŠ³å¯ããä»ã现èãçµç¹ã«å¯ŸããŠä»ã®æ€æ»ãæœè¡ããŸãã
骚é«ç©¿åºã»çæ€ãå°ç¯å²ã®ç®èã«å±æ麻é ãè¡ã£ãåŸã«ãJamshidi éïŒé·ãäžç©ºéïŒãæ£è ããã®éªšç€éªšã«æ¿
å ¥ããŸããæ¡åãããè¡æ¶²ã骚ããããŠéªšé«ã¯é¡åŸ®é¡äžã§èŠ³å¯ãããŸãã
![Page 21: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/21.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 20
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
骚é«ç§»æ€
倧éæããå€ãæŸå°ç·æ²»çã«ãã£ãŠç Žå£ããã骚é«ãæ°ãã«çœ®ãæããææã移æ€ã«ã¯ãèª
家ïŒæ²»çåã«èªä¿¡ã®éªšé«ãä¿åããŠããïŒãåçš®ïŒä»äººããäŸäžããã骚é«ïŒãåç³»ïŒäžåµ
æ§åçå ããã®éªšé«ïŒããããŸãã
骚é«èœç
骚é«ã§ç£çãããæãæªçãªçœè¡çã®ããšã§ããåŸã«ããæçããçœè¡çãžãšååããŸãã
æ ¹æ²»çæ²»ç
ç æ°ãã±ã¬ãæ ¹çµ¶ãŸãã¯æ²»çãããããšãç®çãšããæ²»çã®ããšã§ããç æ°ã«äŒŽãçç¶ãå
ãé€ãããšãç®çãšããç·©åçæ²»çã®å¯ŸçŸ©èªã§ãã
åŸéªšé«ç
骚é«èœçããååãããæçéäžã®çœè¡çã§ããåŸã«ããæçããçœè¡çãžãšååããŸãã
åçºïŒRecurrenceïŒ
éåžžã¯ããããçŸæ£ãèªããªããæ€åºã§ããªãæéããã°ããç¶ããåŸã«ãåã³çºçããã
ããçŸæ£ïŒéåžžãèªå·±å ç«çŸæ£ïŒã®ããšãåçºã¯ãæåã«çºçããïŒåçºïŒè «çãšåãéšäœ
ã«åçºããå Žåãããã°ãå¥ã®éšäœã«åçºããå ŽåããããŸããåçºãããåçºæ§çŸæ£ãšã
åŒã°ããŸãã
åçºïŒRelapseïŒ
ç ç¶ãæ¹åããåŸã«ãæ¹ååã®ç¶æ ã«æ»ãããšãããã«ãããŠã¯ãäžæŠå¯è§£ã«ãªã£ãããšã§ã
ãã现èããµããã³åºçŸããããšã
现èéºäŒåŠ
éºäŒåãšæè²äœã®ç 究ã®ããšãéºäŒåãæè²äœã®å€åã調ã¹ãããšã§ã现èãæ£åžžãçœè¡å
ããŠãããã©ãã決å®ããããšãã§ããŸããçœè¡ç ã®ããã€ãã®ç åã¯ãæçŽã®ããã«ãå ±
éã®çŽ°èéºäŒåŠçç°åžžïŒéºäŒåãæè²äœãžã®å€åïŒãæããŸããããã¯ç çå»ãæ£è ããã®
çœè¡ç ã®ç åãç¹å®ããã®åœ¹ç«ã¡ãŸãã
现èéºäŒåŠçå¯è§£ïŒCCgRïŒ
è¡ãããæ²»çã«å¯Ÿããå¹æãè¡šãæ¹æ³ã® 1 ã€ã§ããCML ã«é¢ããŠã¯ã骚é«ããã³è¡æ¶²äžã«
眮ããïŒç°åžžãªïŒãã£ã©ãã«ãã£ã¢æè²äœ*ãæã€çŽ°èãæžå°ããå²åã«ãã£ãŠè©äŸ¡ããŸãã
现èå¢æ®
现èã®æé·ãåè£ã®çµæã现èã®æ°ãå¢å ããããšã§ãã
现èæ¯æ§
现èã«å¯Ÿããæ¯æ§ã®ããšãæããŸãã
éåŠçæ²»ç
è€æ°ã®å°éåéãæ²»çæ段ãçšããŠæ²»çã«ãããããšã§ããå»ççŸå Žã§ã¯ãå»çè ã ãã§ãª
ãå»çè 以å€ã®å¥åº·ã«é¢ããæ§ã ãªå°éè·çš®ã®ç¥èãåãããŠæ²»çã«ãããããšãå¿ èŠãšã
ããŠããŸãã
![Page 22: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/22.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 21
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
蚺å¯
ç æ°ã®äžè¬çãªå åã調ã¹ã身äœã®æ€æ»ã
èµ€è¡ç
æãäžè¬çãªè¡çãè¡æ¶²ãèµ€ãèŠããç©è³ªãé žçŽ ã®èŒžéãäž»ãªåœ¹å²ã§ãã
æè²äœ
髪ã®æ¯ã®è²ãæ§å¥ãªã©ã®èº«äœçç¹åŸŽãã³ãŒãããéºäŒåãã³ãŒãåããçµç¹æ§é ããã现è
ã¯ã23 察ã®æè²äœïŒ46 ã®æè²äœã®åèšïŒããããŸãããããŸãã¯çœè¡ç 现èã¯ããã°ã
ã°æè²äœéè€ãæè²äœéå°ïŒ47 ã®æè²äœïŒããæè²äœæ¬ 倱ãŸãã¯æè²äœåªå€±ïŒ45 ã®æè²
äœïŒãšãã£ãæè²äœç°åžžãæã¡ãŸããæè²äœãããã¯éºäŒåéäœã¯ãæè²äœã®éå°ã»åªå€±ã¯
ãªãããäžéšãéåãã«ãªããŸãã
çµç¹é©åæå
äœå ã«ããã»ãŒå šãŠã®çŽ°èè¡šé¢ã«ååšããã¿ã³ãã¯è³ªã§ãèªèº«ã®å ç«ã·ã¹ãã ãèªå·±ã®çŽ°è
ãå€ããäœå ã«å ¥ã£ãŠããç©è³ªããèå¥ããæå©ããããŸããçµç¹é©åæåã¯çœè¡çè¡šé¢ã«
å€ãååšããŠãããããçœè¡çæåïŒHLAïŒãšãåŒã°ããŠããŸãã
ããµããã
ããµãããã¯ã¿ã³ãã¯è³ªãªã³é žåé µçŽ é»å®³å€ãšåŒã°ããè¬ã®ã°ã«ãŒãã«å±ããŸãããããã®
ååç©ã¯ã¿ã³ãã¯è³ªãªã³é žåé µçŽ ïŒãããã€ã³ãããŒãŒïŒãšããŠç¥ãããè€æ°ã®é µçŽ ãé»å®³
ããããšã§å¹æãçºæ®ããŸããããµããã㯠Bcr-Abl ãããã€ã³ãããŒãŒãäž»ã«é»å®³ããŸ
ãããã®é µçŽ ã¯çœè¡ç 现èã«ãã£ãŠäœãããçœè¡ç 现èãç¡ç§©åºã«å¢æ®ãããåå ãšãªããŸ
ããä»ã®ãããŒãŒãšåæ§ã« BCR-ABL ãããŒãŒãé»å®³ããããšã«ãããããµãããã¯çœè¡
ç 现èã®å¢æ®ãå¶åŸ¡ããæå©ããããŸãã
ã¿ã³ãã¯è³ª
ã¢ããé žã§æ§æãããéèŠãªæ é€åãã¿ã³ãã¯è³ªã¯äººéãå«ãå€ãã®çç©ã«ãšã£ãŠäžå¯æ¬ ã§ãã
现èéã®èŒžéã»äŒéãååŠå€åã现èã®æ§é ç¶æã®åœ¹å²ãæã¡ãŸãã
äžæ¢ç¥çµïŒCNSïŒ
è³ãšèé«ãããªãç¥çµç³»ã®äžéšã§ãã
ããã·ã³ãããŒãŒé»å®³è¬
现èã®äŒéãå¢æ®ãé»å®³ããè¬å€ã§ãè «çå¢å€§ãæå¶ãããããã€ãã®ããã·ã³ãããŒãŒé»
害è¬ã¯ããæ²»çã«çšããããŠããŸãã
æµææ§ïŒæ²»çã«å¯ŸããïŒ
å»çã§ãç æ°ãäœèª¿ãæ²»çã«ãã£ãŠå¥å¹ããªãããšã
転移
身äœã®ããå Žæããä»ã®å Žæãžãšãããæ¡ããããšãæ¡ãã£ã现èã«ãã£ãŠåœ¢æãããè «ç
ã¯è»¢ç§»è «çã転移ãšåŒã°ããŸããè»¢ç§»è «çã¯åçºã®è «çãšããªã现èãå«ã¿ãŸãã
![Page 23: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/23.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 22
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
ç¹ç¶åºè¡
æ¯çŽ°è¡ç®¡ã®ç Žç¶»ã«ãã£ãŠçãããå°ããªèµ€ã玫ã®åºè¡ã®ããšã§ãã
çªç¶å€ç°
éºäŒåã圢æãã DNA ã«ãããŠãå¡©åºå¯Ÿã®äžŠã³ãå€åããããšãéºäŒåå€ç°ã«ãããå¿ ã
ããéºäŒåãæ°žä¹ çã«å€åããããã§ã¯ãããŸããã
ããããã
ãããããã¯èçœãããŒãŒé»å®³è¬ã§ãBcrâAbl ãããŒãŒãé»å®³ããããšã§äœçšãçºæ®ããŸ
ããBcrâAbl ãããŒãŒã¯çœè¡ç 现èã«ãã£ãŠç£çãããçœè¡ç 现èã®å¢æ®ã«é¢äžããŸãã
ãããããã¯ããã® BcrâAbl ãããŒãŒãé»å®³ããããšã«ãã£ãŠçœè¡ç 现èãå¢æ®ããã®ã
æããŸãã
蟲è¬ïŒæ®ºè«å€
æè«ã害è«ã殺ãããã«äœ¿çšãããç©è³ªã§ãã
çœè¡çïŒLeukocyteïŒ
White blood cell ãšåãæå³ãææãã身äœãå®ã圹å²ãæ ããå ç«ç³»ã®çŽ°èã
ããããã·ãŠã¬ã¢
代è¬æ®æè¬ãšåŒã°ããè¬ç©çŸ€ã«å±ããæããå€ã§ãã
æšçæ²»çã»çæ³
ç¹å®ã®ãã现èãèŠã€ããæ»æããããã«ã¢ãã¯ããŒãã«æäœãªã©ã®è¬å€ãç©è³ªã䜿çšãã
æ²»çæ³ãæšçæ²»çã¯ä»ã®ããæ²»çæ³ããå¯äœçšãå°ãªãããšããããŸãã
貧è¡
èµ€è¡ç*ãŸãã¯ãã¢ã°ããã³*ã®äžè¶³ã«ãã£ãŠç¹åŸŽä»ããããç¶æ ããã¢ã°ããã³ãå«ãéã¯
èºããå šèº«ãžãšé žçŽ ãéã³ãŸããã貧è¡ç¶æ ã§ã¯ãã®é žçŽ éæ¬ã¯æžå°ããŸãã
ç çåŠè
é¡åŸ®é¡äžã§çŽ°èãšçµç¹ã芳å¯ããããšã«ãã£ãŠãç æ°ã確èªããå»åž«ã
ãã£ã©ãã«ãã£ã¢æè²äœ
22 çªæè²äœã®äžéšã« 9 çªæè²äœã転äœããç°åžžã§ãããã®ç°åžžã¯æ ¢æ§éªšé«æ§çœè¡ç ã§ãã
èªããããŸãã
ãã©ããŒã¢ããïŒçµé芳å¯
æ²»çåŸã®æ£è ããã®å¥åº·ç¶æ ã芳å¯ããããšãèšåºç 究ãèšåºè©Šéšã«åå ãã被éšè ã®ãç 究äž
ãŸãç 究åŸã«ãããå¥åº·ç¶æ ã®äžå®æéã«æž¡ã远跡ãå«ãŸããŸãã
è ¹éš
äœã®èžãšè °ã®éã®éšäœããã®éšäœã«ä»éããçèã¯èãè žãèèãèŸèãèµèãå«ãäœè ã
圢æããŠããŸãã
![Page 24: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/24.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 23
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
åååŠçåå¿
æ²»çå¹æãå€å®ããæ¹æ³ã® 1 ã€ã§ããCML ã§ã¯ããªã¡ã©ãŒãŒéåå¿(PCR)ãšåŒã°ããæ€æ»
ã§é°æ§ã§ããããšã瀺ããŸãããã®æ€æ»ã¯ãçœè¡ç 现èã極ããŠå°ãªããä»ã®æ€æ»ã§æ€åºã
ããªãå Žåã«ãçœè¡ç 现èãããªãããšã確èªããããã«è¡ãããŸããPCR ã¯çœè¡ç 现è
ãç£çããç©è³ªãæ€åºããŸãã
åè£æ
è€è£œãããæè²äœã现èã®äžå€®ã«äžçŽç·ã«ãªãåè£ãã现èåè£æã®ããšã§ãããã®åŸçŽ°è
㯠2 ã€ã®çŽ°èã«åè£ããåã åãæ°ã®æè²äœãåé ãããŸãã
ãããã¯ãªããå€
è¡æ¶²å ã§ã®èµ€è¡çã®äœç©æ¯çã瀺ããããŒã»ã³ãã§è¡šãããŸãã
ãã¢ã°ããã³å€
èµ€è¡çã«å«ãŸãããã¢ã°ããã³ãšåŒã°ããã¿ã³ãã¯è³ªãå®éçã«æž¬å®ãããã®ã§ãããåäœ
容ç©ïŒãã·ãªããã«ïŒãããã®éãïŒã°ã©ã ïŒã§è¡šçŸãããŸãããã¢ã°ããã³ã¯äœå ã§é žçŽ
ãéæ¬ããŸãã
ãã³ãŒã³
ååŠå·¥æ¥ã§åºã䜿ãããŠããååç©ã§ãç èãææ°ã¬ã¹ãã¬ãœãªã³ã®æ°åç©ã«ãå«ãŸããŠã
ãŸãããã³ãŒã³ã«æŽé²ãããããšã«ãããçœè¡ç åã®ãªã¹ã¯ãé«ããå¯èœæ§ããããŸãã
æŸå°ç·
æŸå°ç·ã¯ç©ºéã移åãããšãã«ã®ãŒãšå®çŸ©ãããŸããæŸå°ç·ã®äŸãšããŠã¯ UVïŒçŽ«å€ç·ïŒã
X ç·ãããããããã¯å»çã§äžè¬çã«çšããããŸãã
æŸå°ç·çæ³
äœçœ®ãäžå®ã§ããããã«å¯ŸããŠæŸå°ç·ãçšããæ²»çã
ãã¹ããã
æ ¢æ§éªšé«æ§çœè¡ç ïŒCMLïŒã®æ²»çè¬ã§ããä»ã®æ²»çæ³ãå¯äœçšãªã©ã«ããæ²»çãã§ããªãã
ãããã¯æ²»çåŸã«æ¹åããªãã£ãæ£è ããã«å¯ŸããŠäœ¿çšãããŸããéãçš®é¡ã®ããçš®ã®æ²»ç
ã«ã€ããŠãç 究ãããŠããŸãããã¹ããã㯠BCR-ABL ããã®ä»ã®ãã现èã®å¢æ®ãç¶æ
ããã¿ã³ãã¯è³ªã®åããæå¶ãããã现èãæ»æ» ãããŸããããã·ã³ãããŒãŒé»å®³å€ã®ã²ãš
ã€ã§ãã
ããããã
CML ãšãã£ã©ãã«ãã£ã¢æè²äœ(Ph)éœæ§ã® ALL ã®æ£è ããã«äœ¿ãããè¬ã§ããT351I å€
ç°ãæã£ãŠãã CML ã¯ã€ãããããªã©ä»ã®ããã·ã³ãããŒãŒã«ããæ²»çã«å¯Ÿãæµææ§ãæ
ã£ãŠããŸãããããããã¯ãã®ç¹ç°çãªå€ç°ã®ãã CML ã«äœ¿ãããŸãã
麻é
麻é è¬ãšããŠç¥ãããŠããè¬å€ã䜿çšããããšã§ãå¯éçã«æèã®ãªãç¶æ ãšããçã¿ãé€
ããæ£åžžãªåå°ãæããã¹ãã¬ã¹ã«å¯Ÿããåå¿ã匱ããŸããå šèº«éº»é ãå±æ麻é ãè¡ãããš
ã«ãã£ãŠãæ£è ããã骚é«æ¡åãªã©ã®å€ç§çåŠçœ®ãå¯èœãªç¶æ ã«ããŸãã
![Page 25: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/25.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 24
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
æ ¢æ§
é·æéç¶ç¶ããŠããããšãçŸæ£ãç¶æ ãè¿°ã¹ãã®ã«äœ¿ãããå Žåã¯ããããé·ãæéãæç¶
æ§ãããã¯é²è¡æ§ã§ããããšãæå³ããã
ç¡çç¶ã®
çã¿ãç æ°ã®èªèŠããã城åã®ãããªçç¶ãç¡ãããšã
å ç«ç³»
å ç«ç³»ã¯ããã现èãšãŠã€ã«ã¹ã现èãªã©ã®å€çäŸµå ¥ç©ãèªèãæ»æ» ãããããšã«ãããç
æ°ãã身äœãä¿è·ããæ©æ§ãéçšã®çåœã·ã¹ãã ã®äžã€ã§ãã
è¬å€ä»£è¬
é µçŽ ã«ãã£ãŠè¬ãå解ããä»çµã¿ãäœã®äžã«ã¯ååšããããã«ããè¬ãäœå ã§äœçšããåŸã«
äœå€ã«æåºãããããšãå¯èœã«ããŸãã
æå¹æ§
å»åŠã®åéã§ã¯ãããæ²»ççä»å ¥æ¹æ³ãäŸãã°è¬ãæè¡ã«ãã£ãŠæãŸããæçãªå¹æããã
ããèœåã®ããšããããŸãã
äºåŸ
ãã®çŸæ£ã®ãã©ããšæãããçµæãŸãã¯çµéïŒå埩ã®èŠèŸŒã¿ãŸãã¯åçº*ã®èŠèŸŒã¿ã®ããšã§
ãã
ãªã¹ã¯å åïŒå±éºå å
ç æ°ãé²è¡ãããæ©äŒãå¢å ããããªã«ãã§ããããã®å±éºå åãšããŠäŸãæãããšã幎霢ã
幎霢ãç¹å®ã®ããã®å®¶ææŽãå«ç ç¿æ £ãæŸå°ç·*ãŸãã¯ç¹å®ã®ååŠè£œåãžã®æŽé²ãç¹å®ã®ãŠ
ã€ã«ã¹ãŸãã¯çŽ°èãžã®ææããªãã³ã«ç¹å®ã®éºäŒåå€åããããŸãã
èšåºçå¹æ
è¡ãããæ²»çã«å¯Ÿããå¹æãè¡šãæ¹æ³ã§ããç æ°ã«ããçç¶ãå åã®å€åãçšããŠè©äŸ¡ããŸ
ãã
èšåºè©ŠéšïŒæ²»éšïŒ
æ°è¬ã®èšåºè©Šéšããã°ãã°è»¢ç§»æ§ä¹³ããã®æ£è ããã«ææ¡ãããŸããæ²»çãéåžžã«å°é£ãªçŸ
ç¶ãæéããããã®å¯äžã®æ¹æ³ã§ãããããèšåºè©Šéšãžã®åå ãæšå¥šãããŸãã
ãªã³ãç茞泚
é è¡å¹¹çŽ°è移æ€ããããæ£è ãããããããŒç±æ¥ã®ãªã³ãç茞泚ããããæ²»çæ³ã®ããšã§ãã
ãããŒã®ãªã³ãçã¯æ®ã£ããã现èãå·å®³ããããšãç¥ãããŠãããåçºããæ ¢æ§éªšé«æ§çœ
è¡ç (CML)ã骚é«è «ã®æ²»çã«äœ¿ãããŸãããŸããä»ã®ããã®æ²»çæ³ãšããŠãç 究ãããŠããŸ
ãããªã³ãçã¯å ç«ç³»ã«ãããŠéèŠãªåœ¹å²ãæ ãçœè¡çã§ãã䞻㫠T 现èãB 现èãNK 现
èãšãã 3 ã€ã®ã¿ã€ãããããå ç«ç³»ã«ãããŠããããã®åœ¹å²ãæ ã£ãŠããŸãã
![Page 26: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/26.jpg)
CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 25
This document is provided by the Anticancer Fund with the permission of ESMO. The information in this document does not replace a medical consultation. It is for personal use only and cannot be modified, reproduced or disseminated in any way without written permission from ESMO and the Anticancer Fund.
ãªã³ãç¯
ãªã³ãçµç¹ã®äžžãå¡ã§ãåšå²ã¯çµåçµç¹ã®è¢«èã«èŠãããŠããŸãããªã³ãç¯ã§ã¯ãªã³ãã®æ¿Ÿ
éãè¡ãããŠããã»ãããªã³ãçã®è²¯èµå Žæã«ããªã£ãŠããŸãããªã³ãç¯ã¯ãªã³ã管ã«æ²¿ã£
ãŠååžããŠããŸãããªã³ãè ºãšãåŒã°ããŸãã
![Page 27: ESMO-ACF CML: Guide for Patients - JapaneseCML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 4 This document is provided by the Anticancer](https://reader033.vdocuments.net/reader033/viewer/2022053110/60801f785e679342f95cbc1b/html5/thumbnails/27.jpg)